16 November 2026
by Joanne S. Eglovitch

Industry groups seek clarifications in FDA’s ANDA and 505(b)(2) guidance

FDA_Sign_260416_ALF.png
FDA headquarters in Silver Spring, Md. (credit: Ferdous Al-Faruque) 

Brand-name and generic pharmaceutical groups are recommending clarifications to the US Food and Drug Administration’s (FDA) guidance on when to submit an abbreviated new drug application (ANDA) or a 505(b)(2) new drug application (NDA), though the groups had different stances on what changes are necessary.

In its comments, the Pharmaceutical Research and Manufacturers of America (PhRMA) said it wants FDA to maintain clear distinctions between these pathways, while the Association for Accessible Medicines (AAM) advocated for more flexibility in the approval processes.

These comments were a response to FDA's draft guidance, which clarifies the differences among abbreviated approval pathways and the data it will accept for these applications. The draft guidance was issued in August 2026 and will replace an earlier version from 2019 when finalized. (RELATED: FDA issues draft guidance clarifying differences between ANDAs and 505(b)(2) applications, Regulatory Focus 18 August)

The ANDA pathway is for a product that is a duplicate of a previously approved drug product and relies on FDA’s finding that the previously approved reference listed drug (RLD) is safe and effective.

Drugs that can be submitted through the 505(b)(2) pathway include new versions of approved drugs that differ in the RLD in terms of active ingredient, dosage form, strength, route of administration, formulation, or when there is a new indication. Applications submitted through this route can include full reports of safety and effectiveness investigations.

In its comments PhRMA urged the agency to maintain the “longstanding distinction between these pathways.” The group also emphasized the importance of promoting “predictability for applicants and stakeholders” while avoiding “interpretations that blur the boundary between the products appropriately reviewed through each pathway.”

Additionally, PhRMA noted that “several aspects” of the guidance “would benefit from additional clarification to ensure that the statutory framework established by Congress continues to be applied consistently and transparently.”’

In contrast, AAM said that its members “believe that clarifying and broadening the circumstances under which an applicant can submit a 505(b)(2) NDA or ANDA are legally and scientifically justifiable, would enhance predictability in the assessment process, and would encourage competition, helping to provide more timely patient access to safe, effective and affordable generic medicines.”

Alternative BE approaches for discontinued drugs

AAM recommended that FDA clarify in its final guidance the various types of alternative methods that generic manufacturers can use to assess bioequivalence when the RLD and its reference standard are no longer available due to the discontinuation of the drug and its removal from the Orange Book.

The guidance indicates that for discontinued drugs, “It might be appropriate for a prospective applicant to consider whether alternate methods to establish bioequivalence are adequate for the proposed drug product to be eligible for approval under section 505(j) of the FD&C Act.” However, FDA does not specifically recommend any methods.

AAM suggested that these alternative methods may include utilizing RLDs from other countries that have scientific and regulatory standards comparable to those of FDA. This is applicable to countries that are members of the International Conference on Harmonisation (ICH).

Inactive ingredients

AAM also urged FDA to broaden its criteria for determining if generic parenteral, ophthalmic, and otic products can contain different inactive ingredients than the RLD.

The guidance states that for these drug products, permissible changes to inactive ingredients in an ANDA have been limited by regulation. For example, parenteral drug ANDAs must generally contain the same inactive ingredients and in the same concentrations as the RLD. “However, specific qualitative and quantitative changes from the RLD formulation are permitted in an ANDA for a parenteral drug product for certain inactive ingredients (i.e., preservatives, buffers, and antioxidants) that are considered exception excipients.  All other inactive ingredients in a proposed parenteral drug product must be qualitatively and quantitatively the same (Q1/Q2 same) as the RLD.”

AAM states that “the draft guidance does not change the fundamental premise that non-exception excipient differences default into the 505(b)(2) NDA pathway despite FDA’s recognition that inactive ingredient differences do not necessarily affect safety, efficacy, or bioavailability. We recommend that FDA take further steps to loosen this overly restrictive approach to formulation sameness for parenteral, ophthalmic, and otic products.”

A non-exception excipient is an inactive ingredient in a generic drug product that must be qualitatively Q1/Q2 the same as the inactive ingredient in the RLD.

Limited confirmatory studies

PhRMA requested that FDA narrow the scope of the “limited confirmatory studies” that the agency proposes to accept in an ANDA.

The guidance indicates that ANDA applicants have “significant flexibility” in the types of studies they can submit to support approval, provided that these studies are not necessary to establish the safety or effectiveness of the drug product.

It also notes that “FDA has accepted limited confirmatory studies” for ANDAs that have been subject to a suitability petition.

“The draft guidance refers to ‘limited confirmatory clinical testing’ as potentially being acceptable in an ANDA, and this statement appears to depart from FDA precedents. Further, it remains unclear which other types of studies FDA deems ‘limited confirmatory studies’ that may support an ANDA and which types of studies FDA deems to establish safety and effectiveness and thus, considers impermissible in an ANDA. Outside the context of specific products and product categories, it appears that FDA’s only prior discussion of its overarching policy on limited confirmatory testing was published over 25 years ago, focused on suitability petitions, and did not contemplate limited confirmatory clinical testing,” PhRMA wrote.

Furthermore, the group highlighted that FDA should clarify that the scope of confirmatory studies supporting an ANDA is limited.

“After more than 30 years of experience implementing the Hatch-Waxman Amendments, FDA should be well-positioned to provide greater details and clarity regarding the distinction between limited confirmatory studies and studies that establish safety or effectiveness. In finalizing the 2026 Draft Guidance, FDA should clarify that the scope of confirmatory studies that may support an ANDA is narrow,” PhRMA wrote.

Comments

Related topics